Concept Life Sciences offers tailored preclinical services in areas including investigative and mechanistic toxicology exploratory and discovery toxicology PK and metabolism and dermal absorption as well as providing integrated drug discovery programs.
Graeme will be responsible for supporting investigative toxicology and drug discovery customer programs in his particular areas of expertise; bioanalysis metabolism and pharmacokinetics of small molecules industrial chemicals mixtures oligos peptides
and biotherapeutics as well as in vitro to in vivo extrapolation analytical read-across approaches for e.g. REACH.
Graeme has over 17 years’ experience in bioanalytical and biotransformation sciences within a wide range of environments such as academia biotech large pharma and contract research. Since obtaining his PhD in Bio-organic chemistry in 1999 Graeme has held positions of increasing responsibility and led groups in support of studies ranging from Discovery though to Phase IIb clinical trials. Previously he was an Associate Research Fellow at Pfizer within the Pharmacokinetics Dynamics and Metabolism division and amongst other roles was the global technical lead on the implementation of microsampling strategies for Pfizer’s small molecule portfolio. Most recently he has spent the past 6 years at the Head of Analytical Sciences at Cyprotex building and leading their analytical group in support of HT Analysis Bioanalysis/PK and Biotransformation disciplines.
Graeme brings with him a broad skill set in the analysis of varying modalities including: small molecule (pharma and agrochem) lipidomics peptides oligonucleotides and protein based biotherapeutics. He is a Fellow of the Royal Society of Chemistry (FRSC) a Fellow of the Royal Society of Biology (FRSB) A Chartered Chemist (CChem) and Chartered Scientist (CSci). Graeme is also highly active within the Drug Metabolism Discussion Group (DMDG) and is currently course organiser for their Large Molecule training course which runs biennially.
Commenting on his appointment Dr Graeme Clark stated: “I am delighted to be joining Concept Life Sciences at this exciting time in its development. The Dundee team is generally recognised as the leading global provider of preclinical investigative and exploratory toxicology services and I look forward to bringing my bioanalytical and metabolism expertise to bear for our clients. I also look forward to supporting the groups many integrated discovery and development partners from virtual biotechs to big pharma with their bioanalytical and DMPK needs.”
Commenting on Dr Clarke’s appointment Dr Paul Doyle Chief Scientific Officer at Concept Life Sciences said: “Concept Life Sciences Dundee is already the leading provider of investigative toxicology services to the life sciences industry. I am thoroughly delighted to welcome Dr Graeme Clark to the team. Dr Graeme’s expert knowledge and track record in this field will further enhance our position as a leading provider of integrated discovery and development services for the life sciences sector.”